Year 2022 / Volume 114 / Number 4
Editorial
Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease

191-194

DOI: 10.17235/reed.2022.8718/2022

Antonio Liguori, Mirko Zoncapè, Emmanuel A. Tsochatzis,

Abstract
In the last two decades, several non-invasive liver fibrosis tests have been introduced in clinical practice and transformed the investigation of patients with non-alcoholic fatty liver disease. In this editorial, we summarize the role of such tests in the management of patients with non-alcoholic fatty liver disease, focusing on their strengths and pitfalls in different clinical settings and scenarios.
Share Button
New comment
Comments
No comments for this article
References
1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology. 2018;15(1):11-20.
2. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-397.e10.
3. Taylor RS, Taylor RJ, Bayliss S, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611-1625.e12.
4. Berzigotti A, Tsochatzis E, Boursier J, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. Journal of Hepatology. 2021;75(3):659-689.
5. McPherson S, Hardy T, Dufour JF, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. The American journal of gastroenterology. 2017;112(5):740-751.
6. Liguori A, Ainora ME, Riccardi L, et al. The role of elastography in non-alcoholic fatty liver disease. Minerva gastroenterology. 2021;67(2):164-170.
7. Miele L, Zocco MA, Pizzolante F, et al. Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental. 2020;112.
8. Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486-1501.
9. Majumdar A, Campos S, Gurusamy K, et al. Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. Hepatology (Baltimore, Md). 2020;71(2):627-642.
10. Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. The lancet Gastroenterology & hepatology. 2018;3(7):509-517.
11. Vali Y, Lee J, Boursier J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of hepatology. 2020;73(2):252-262.
12. Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2019;71(2):371-378.
13. de Franchis R, Abraldes JG, Bajaj J, et al. Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of Hepatology. 2015;63(3):743-752.
14. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2021 Dec 30:S0168-8278(21)02299-6.
15. Papatheodoridi M, Hiriart JB, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. Journal of Hepatology. 2021;74(5):1109-1116.
16. Petta S, Sebastiani G, Bugianesi E, et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. Journal of hepatology. 2018;69(4):878-885.
17. Pons M, Augustin S, Scheiner B, et al. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. The American journal of gastroenterology. 2021;116(4):723-732.
18. Thiele M, Hugger MB, Kim Y, et al. 2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. Liver Int. 2020 Jun;40(6):1435-1446.
19. Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1877-1885.e5
20. Petta S, Sebastiani G, Viganò M, et al. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clin Gastroenterol Hepatol. 2021 Apr;19(4):806-815.e5.
21. Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2021;75(4):786-794.
22. Francque SM, Bedossa P, Ratziu V, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. New England Journal of Medicine. 2021;385(17):1547-1558.
23. Rinella ME, Dufour JF, Anstee QM, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2021 Nov 15:S0168-8278(21)02177-2.
24. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021;384(12):1113-1124.
25. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59(9):1245-1251.
Related articles

Editorial

Treatment of portal vein thrombosis in cirrhosis patients

DOI: 10.17235/reed.2023.9800/2023

Editorial

AKI-HRS, more than a name change for type-1 hepatorenal syndrome

DOI: 10.17235/reed.2023.9677/2023

Letter

Esophageal stent placement for endoscopic treatment failure

DOI: 10.17235/reed.2023.9517/2023

Letter

Tolvaptan in portal hypertension: real life experience

DOI: 10.17235/reed.2022.9145/2022

Editorial

New actors come into play against hepatitis delta

DOI: 10.17235/reed.2022.9050/2022

Letter

Hemoperitoneum due to rupture of intra-abdominal varices

DOI: 10.17235/reed.2022.8937/2022

Digestive Diseases Image

Traumatic high flow arterioportal fistula. Correction by a covered stent

DOI: 10.17235/reed.2022.8724/2022

Letter

Cirrhotic pattern in advanced hepatic sarcoidosis

DOI: 10.17235/reed.2021.8446/2021

Digestive Diseases Image

Giant cystic hepatocarcinoma in the absence of cirrhosis

DOI: 10.17235/reed.2021.8313/2021

Review

Physical frailty in liver transplantation

DOI: 10.17235/reed.2020.7448/2020

Letter

Stomal varices: an unusual cause of bleeding in liver cirrhosis

DOI: 10.17235/reed.2020.6470/2019

Review

Risk stratification and treatment of primary biliary cholangitis

DOI: 10.17235/reed.2018.5662/2018

Letter to the Editor

Late migration of a metal stent after EUS-drainage of a pancreatic pseudocyst abscess

DOI: 10.17235/reed.2018.5411/2017

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Letter to the Editor

POEMS syndrome and idiopathic portal hypertension: a possible association

DOI: 10.17235/reed.2017.4623/2016

Original

Self-expanding metal stents in postoperative esophageal leaks

DOI: 10.17235/reed.2016.3987/2015

Citation tools
Liguori A, Zoncapè M, Tsochatzis E. Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease. 8718/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1200 visits.
This article has been downloaded 409 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 15/02/2022

Accepted: 16/02/2022

Online First: 21/02/2022

Published: 07/04/2022

Article Online First time: 6 days

Article editing time: 51 days


Share
This article has been rated by 4 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology